Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:46 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 5,569 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Recruiting No phase listed Observational

Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)

NCT05139797
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
EchoNet-LVH screening for cardiac amyloidosis
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional

The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms

NCT04829760
View directory record Official record
Conditions
Parkinson Disease
Interventions
Psyllium, Coarse wheat bran, Maltodextrin
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Nov 2, 2026, 9:46 PM EST
Not listed Phase 2 Interventional

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

NCT02149160
View directory record Official record
Conditions
Granulin Mutation
Interventions
FRM-0334, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Nov 2, 2026, 9:46 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease

NCT01155492
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 3 Interventional Results available

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional Results available

EMPOWER PD - Feasibility of an Interdisciplinary Clinic for People With Parkinson's Disease

NCT05640167
View directory record Official record
Conditions
Parkinson Disease
Interventions
Interdisciplinary Clinic
Behavioral
Lead sponsor
University of Rhode Island
Other
Eligibility
40 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 3 Interventional Results available

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders

NCT05474235
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2038
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Terminated Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT02670083
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
66
States / cities
Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 1 Interventional

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

NCT02460094
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 2 Interventional Results available

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

NCT02167256
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD0530 100mg daily, AZD0530 125mg daily, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
55 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD

NCT06055322
View directory record Official record
Conditions
Suicide, Depression, Caregiver Burden, Physical Health, Inflammation
Interventions
Adapted Dialectical Behavior Therapy
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572
View directory record Official record
Conditions
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
Interventions
IDE574, Fulvestrant injection
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Plantation, Florida • East Brunswick, New Jersey • Lake Success, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics

NCT04578912
View directory record Official record
Conditions
Tic Disorders, Tics, Tic, Motor, Tic Disorder, Childhood, Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
Comprehensive Behavioral Intervention for Tics (CBIT), Repetitive Transcranial Magnetic Stimulation (rTMS), Continuous Theta Burst Stimulation (cTBS)
Behavioral · Device
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Nov 2, 2026, 9:46 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 1 Interventional

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

NCT04774952
View directory record Official record
Conditions
Solid Tumors
Interventions
RMC-5552
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Nov 2, 2026, 9:46 PM EST
Completed No phase listed Observational Accepts healthy volunteers

The DIAGNOSE-CTE Research Project

NCT02798185
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
45 Years to 74 Years · Male only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional

Pilot Study of a Brain Health Program in Senior Centers

NCT07424443
View directory record Official record
Conditions
Memory Loss (Excluding Dementia), Lifestyle (Sedentary Behavior and Physical Activity), Lifestyle Risk Reduction, Healthy Lifestyle Behaviors, Dementia Prevention
Interventions
My Healthy Brain
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Terminated Phase 2 Interventional Results available

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

NCT00916617
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Nov 2, 2026, 9:46 PM EST
Completed Not applicable Interventional

Exercise for Cognitive Excellence in Parkinson's Disease

NCT05720468
View directory record Official record
Conditions
Parkinson Disease
Interventions
Exercise, No Exercise
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

NCT02281474
View directory record Official record
Conditions
Parkinson's Disease, Parkinson's Disease Dementia, Diffuse Lewy Body Disease
Interventions
Nilotinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 2 Interventional

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

NCT00795418
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, CAD106
Biological
Lead sponsor
Novartis
Industry
Eligibility
40 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 2, 2026, 9:46 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

NCT04526197
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Celecoxib
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Nov 2, 2026, 9:46 PM EST
Completed No phase listed Observational

Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population

NCT00718497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Nov 2, 2026, 9:46 PM EST